Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Immune Function

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,487 result(s) found for: Immune Function. Displaying page 1 of 75.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2011-005581-37 Sponsor Protocol Number: 5946 Start Date*: 2012-08-06
    Sponsor Name:The Newcastle upon Tyne Hospitals NHS Foundation Trust
    Full Title: Efficacy of Switch to Lopinavir/Ritonavir in Improving Cognitive function in Efavirenz treated patients
    Medical condition: Cognitive function and sleep pattern in HIV-1 patients
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10021425 Immune system disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-004388-20 Sponsor Protocol Number: 1066/08 Start Date*: 2008-09-19
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: MONOCENTRIC, DOUBLE-BLIND, CASE-CONTROLLED STUDY FOR ASSESSMENT OF PRE-SEASONAL SUBLINGUAL SPECIFIC IMMUNOTHERAPY’S EFFECTIVENESS AS A TREATMENT OF GRASS-INDUCED ALLERGIC RHINOCONJUNCTIVITIS
    Medical condition: ALLERGIC RHINOCONJUNCTIVITIS
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021428 Immune system disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000968-30 Sponsor Protocol Number: RC31/19/0509 Start Date*: 2021-04-13
    Sponsor Name:CHU Toulouse
    Full Title: ASPirin in Immune thRombocytopenia patients with cardiovascular disEase
    Medical condition: Immune thrombocytopenia with cardiovascular disease
    Disease: Version SOC Term Classification Code Term Level
    23.0 10005329 - Blood and lymphatic system disorders 10083842 Immune thrombocytopenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001391-42 Sponsor Protocol Number: Speed-Covid Start Date*: 2021-05-12
    Sponsor Name:Medical University of Graz
    Full Title: Characterisation of the effects of Spermidine on the immune response to Covid-19 vaccine in older people - a feasibility study
    Medical condition: For assessing the immune cell function after COVID-19 vaccine, peripheral blood mononuclear cells (PBMC) will be separated after blood sampling and measurements as follows will be done: • FACS anal...
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-004730-34 Sponsor Protocol Number: 361.11 Start Date*: 2011-07-20
    Sponsor Name:OSPEDALE PEDIATRICO BAMBINO GESU' DI ROMA
    Full Title: A phase II multicentre, randomized, controlled open-label study on the use of anti-thymocyte globulin and rituximab for immunomodulation of graft-versus-host disease in allogeneic matched transpla...
    Medical condition: graft-versus-host disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10021428 Immune system disorders SOC
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004910-41 Sponsor Protocol Number: WellmuneElderlyStudy1.1 Start Date*: 2011-12-30
    Sponsor Name:University of Southampton
    Full Title: A Randomised Controlled Trial to assess a food supplement (baker’s yeast extract) to support immune function and prevent cold and flu symptoms in a 50 to 70 year old population
    Medical condition: We aim to assess the number and severity of Upper Respiratory Tract Infection(URTI)Symptoms reported by participants over a 90 day period commencing in January 2012 in 100 healthy 50-70 year olds p...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-005514-18 Sponsor Protocol Number: STH17062 Start Date*: 2013-02-07
    Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust
    Full Title: Study of the Effect of Ticagrelor and Clopidogrel on the Immune Response of Healthy Volunteers
    Medical condition: Immune response to endotoxin influenced by anti-platelet medications.
    Disease: Version SOC Term Classification Code Term Level
    15.1 10021428 - Immune system disorders 10011968 Decreased immune responsiveness PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-003325-22 Sponsor Protocol Number: 2022-15944 Start Date*: 2023-01-25
    Sponsor Name:RadboudUMC
    Full Title: The immunomodulatory effect of sugammadex after total hip replacement surgery under neuraxial anaesthesia: a pilot study
    Medical condition: Hip osteoarthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-006769-95 Sponsor Protocol Number: SSAT030 Start Date*: 2009-06-02
    Sponsor Name:St Stephen's Aids Trust
    Full Title: A Randomised, Placebo Controlled, Phase IV, Safety and Exploratory Immunogenicity Study into the Impact of Maraviroc, an Orally Administered CCR5 Inhibitor, on the Intensification of Immune Functio...
    Medical condition: HIV
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-001923-30 Sponsor Protocol Number: TN-20 Start Date*: 2016-09-26
    Sponsor Name:TRIALNET COORDINATING CENTER AT THE UNIVERSITY OF SOUTH FLORIDA
    Full Title: Exploring Immune Effects of Oral Insulin in Relatives at Risk for Type 1 Diabetes Mellitus
    Medical condition: Type 1 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10066284 Diabetes prophylaxis PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005513-72 Sponsor Protocol Number: B7451006 Start Date*: 2016-07-21
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL, MULTICENTER, DOSE-RANGING, STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-04965842 IN SUBJECTS WITH MODERATE TO SEVERE AT...
    Medical condition: ATOPIC DERMATITIS
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021428 - Immune system disorders 10021428 Immune system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2021-001387-20 Sponsor Protocol Number: ELA026-CP002 Start Date*: 2021-10-11
    Sponsor Name:Electra Therapeutics, Inc.
    Full Title: A Phase 1b, Open-label, Single-arm, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Multiple Doses of ELA026 in Adults and Adolescents with Secondary Hemophagocytic Lymph...
    Medical condition: sHLH is a rare and life-threatening inflammatory syndrome characterized by dysregulated immune function. The disease is associated with a massive systemic inflammatory response for which patients r...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10021428 Immune system disorders SOC
    21.1 10018065 - General disorders and administration site conditions 10058092 Multi-organ disorder PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003377-97 Sponsor Protocol Number: KLLVACC-2018 Start Date*: 2018-12-18
    Sponsor Name:Swedish CLL-group
    Full Title: Long term effect on immune response after pneumococcal vaccination in patients with chronic lymphocytic leukemia and evaluation of the effect of revaccination.
    Medical condition: The aim of the study is to evaluate pneumococcal vaccination strategy with PPSV23 and PCV13 in patients with chronic lymphocytic leukemia (CLL) initially randomized in a clinical study.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001270-34 Sponsor Protocol Number: RIMAL1 Start Date*: 2021-04-19
    Sponsor Name:Radboud University Medical Centre
    Full Title: Enhancement of immune response by combining immune checkpoint blockade and radiation in patients with recurrent / refractory malignant lymphoma (re-directing the immune system).
    Medical condition: patients with recurrent / refractory 9p24.1 amplified malignant lymphomas patients with recurrent / refractory malignant lymphoma without 9p24.1 amplification
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025310 Lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001326-26 Sponsor Protocol Number: NI-0801-03 Start Date*: 2011-05-27
    Sponsor Name:NovImmune S.A.
    Full Title: PIANO. Primary Biliary Cirrhosis: Investigating A New Treatment Option using NI-0801, a fully human anti-CXCL10 monoclonal antibody. An open label single arm study to investigate the safety and eff...
    Medical condition: Primary biliary cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10019805 - Hepatobiliary disorders 10036680 Primary biliary cirrhosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-006188-35 Sponsor Protocol Number: IMMUNEF Start Date*: 2009-01-29
    Sponsor Name:AZIENDA OSPEDALIERA SAN GERARDO DI MONZA
    Full Title: Immunological efficacy of efavirenz based treatment in HIV-positive naive patients (a pylot study)
    Medical condition: HIV infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052740 Acquired immunodeficiency syndromes HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001970-28 Sponsor Protocol Number: CMV-001 Start Date*: 2012-11-20
    Sponsor Name:University of Birmingham
    Full Title: Does CMV reactivation cause functional impairment of CMV specific CD4+ T-cells? The potential for valaciclovir to prevent CMV-mediated adverse modulation of the immune system in patients with ANCA-...
    Medical condition: This study will investigate the modulation of the immune system by Cytomegalovirus (CMV) in ANCA-associated vasculitis. Specifically the study will investigate the potential for valaciclovir to ...
    Disease: Version SOC Term Classification Code Term Level
    15.0 10021881 - Infections and infestations 10011831 Cytomegalovirus infection PT
    15.0 10021428 - Immune system disorders 10050894 Anti-neutrophil cytoplasmic antibody positive vasculitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-002991-42 Sponsor Protocol Number: HCV-13-01 Start Date*: 2013-12-19
    Sponsor Name:Foundation for Liver Research
    Full Title: Effect of ASV and DCV therapy on the quality of immune status in chronic HCV patients Investigator initiated research proposal nr. AI447-108
    Medical condition: Chronic hepatitis C
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023625-38 Sponsor Protocol Number: JF003 Start Date*: 2012-11-13
    Sponsor Name:Guy's and St Thomas' NHS Foundation Trust
    Full Title: Investigating the effect of Maraviroc on microbial translocation in HIV-1 infected individuals who are receiving antiretroviral therapy
    Medical condition: HIV
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10068341 HIV-1 infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-000570-35 Sponsor Protocol Number: 01-2015 Start Date*: 2016-02-10
    Sponsor Name:DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA - UNIVERSITÀ DEGLI STUDI DI NAPOLI FEDERICO II
    Full Title: Prophylaxis of Hepatitis B reactivation in patients with HBV occult infection and rheumatological diseases candidates to immune suppressive treatments of finite duration.
    Medical condition: Occult Hepatitis B virus Infection (OBI) in patients with rheumatologic diseases candidate to treatment a finite duration (less than 18 months) with potent immune suppressive drugs
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10037163 Psoriatic arthropathies HLT
    20.1 100000004862 10057212 Hepatitis viral infections HLT
    20.0 100000004870 10039075 Rheumatoid arthritis and associated conditions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 20:24:42 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA